GlassScriptPhysician profile
Mark W Norton
NPI 1881608495
$4,648.30
in general payments reported to CMS, 2019-2025
39 companies · $317 in 2025
The $317 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,049 · 2020: $664 · 2021: $983 · 2022: $680 · 2023: $435 · 2024: $520 · 2025: $317.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,272.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,272.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $897.17 | 2019-2025 | Ozempic, Rybelsus |
| Merck Sharp & Dohme LLC | $439.17 | 2019-2023 | Verquvo, Steglatro, Steglujan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $358.78 | 2019-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $319.39 | 2019-2025 | Farxiga, Lokelma |
| Astellas Pharma US INC | $268.01 | 2019-2022 | |
| Pfizer INC. | $249.04 | 2019-2021 | |
| Amgen INC. | $245.18 | 2019-2024 | Evenity, Prolia |
| Abbott Laboratories | $223.02 | 2021-2023 | Freestyle Libre |
| Janssen Pharmaceuticals, INC | $219.26 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $171.86 | 2021-2025 | Rexulti |
| E.R. Squibb & Sons, L.L.C. | $142.28 | 2019-2024 | Eliquis |
| Abbvie INC. | $138.75 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $123.68 | 2019-2023 | |
| Sumitomo Pharma America, INC. | $115.69 | 2024-2025 | Gemtesa |
| Inspire Medical Systems, INC. | $106.83 | 2024-2025 | Inspire |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Norton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.